Canaccord Genuity Gives Buy Rating to NuVasive (NUVA)

By admin | 6 years ago

NuVasive (NASDAQ: NUVA)‘s stock had its “buy” rating restated by equities researchers at Canaccord Genuity in a report issued on Tuesday.

NuVasive traded up 2.01% on Tuesday, hitting $20.80. NuVasive has a 1-year low of $11.02 and a 1-year high of $34.91. The company’s market cap is $887.2 million.

The company last announced its quarterly results on Monday, April 30th. It reported $0.20 earnings per share (EPS) for the previous quarter, beating the Thomson Reuters consensus estimate of $0.18 EPS by $0.02. The company’s quarterly revenue was up 21.8% on a year-over-year basis. Analysts expect that NuVasive will post $0.24 EPS next quarter.

Other equities research analysts have also recently issued reports about the stock. Analysts at Robert W. Baird upgraded shares of NuVasive from a “neutral” rating to an “outperform” rating in a research note to investors on Tuesday. Separately, analysts at William Blair upgraded shares of NuVasive from a “market perform” rating to an “outperform” rating in a research note to investors on Tuesday. Finally, analysts at Wells Fargo & Co. (NYSE: WFC) initiated coverage on shares of NuVasive in a research note to investors on Monday, April 9th. They set a “market perform” rating on the stock.

NuVasive, Inc. (NuVasive) is a medical device company. NuVasive focuses on developing minimally disruptive surgical products and procedures for the spine.

About the author